Neurocrine Biosciences (NBIX) Interest & Investment Income (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Interest & Investment Income of $12.4 million for Q2 2026, down 39.81% year-over-year from $20.6 million in Q2 2025, and down 55.87% on a QoQ basis from $28.1 million in Q1 2026.
Neurocrine Biosciences (NBIX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Interest & Investment Income for 17 years, with the latest figure at $12.4 million in Q2 2026.
- Interest & Investment Income for Q2 2026 came in at $12.4 million, down 39.81% year-over-year; the trailing twelve-month figure through Jun 2026 was $88.5 million (changed 0.34% YoY), and the FY2025 annual result was $90.3 million, down 0.77% from the prior year.
- Interest & Investment Income retreated to $12.4 million in Q2 2026, from $28.1 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $28.1 million in Q1 2026 and troughed at $200000.0 in Q3 2022.
- A 5-year average of $15.5 million and a median of $19.8 million in 2023 frame the typical range for Interest & Investment Income.
- The widest annual swing landed in 2022, when Interest & Investment Income plunged 75.0%; it then surged 7150.0% in 2023.
- A 5-year view of Interest & Investment Income shows it stood at $1.3 million in 2022, then jumped by 1353.85% to $18.9 million in 2023, then advanced by 19.05% to $22.5 million in 2024, then advanced by 14.67% to $25.8 million in 2025, then plunged by 51.94% to $12.4 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $12.4 million in Q2 2026, $28.1 million in Q1 2026, and $25.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 5.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.40 Mn |
| Mar 31, 2026 | 28.10 Mn |
| Dec 31, 2025 | 25.80 Mn |
| Sep 30, 2025 | 22.20 Mn |
| Jun 30, 2025 | 20.60 Mn |
| Mar 31, 2025 | 21.70 Mn |
| Dec 31, 2024 | 22.50 Mn |
| Sep 30, 2024 | 23.40 Mn |
| Jun 30, 2024 | 22.80 Mn |
| Mar 31, 2024 | 22.30 Mn |
| Dec 31, 2023 | 18.90 Mn |
| Sep 30, 2023 | 14.50 Mn |
| Jun 30, 2023 | 10.70 Mn |
| Mar 31, 2023 | 9.80 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 700,000.00 |
| Sep 30, 2021 | 800,000.00 |